Weekender 7/29/16

Hope for Patients Around the World…
New Jersey companies once again are represented at the global forefront of developing important drugs to meet significant unmet medical needs, as recognized in recent announcements from Janssen Therapeutics, Sanofi, Eli Lilly and Company and Eisai. Enjoy this week’s edition of the BioLines Weekender chock full of stories of medical innovation.

Industry Insight…
PlanSmart NJ recently announced its findings on underutilized office and retail centers in its Guide to the Future. In response to PlanSmart’s cry to redevelop these “stranded” real estate assets, BioNJ President and CEO Debbie Hart penned an op-ed, published by NJBIZ, emphasizing the opportunity to utilize such real estate to house lab space for startup and emerging life sciences companies. Click here to read.

Funding Opportunities…
The National Center for Advancing Translational Sciences (NCATS) has several open SBIR and STTR program funding opportunities for the following research areas: drug discovery and development, diagnostics and devices, bioinformatics and information technology and clinical research. The deadline for application submission is September 6, 2016. Click here for details.

Registration Opens Next Week…
BioNJ is looking forward to bringing the industry’s thought leaders together at this year’s 4th Annual CEO Summit, September 23, entitled “A Funny Thing Happened on the Way to the Market…With Insights from McKinsey & Company.” We’ll be Taking It Over the Top with top-notch programs and speakers, such as Mark Alles, CEO, Celgene; Jesper Hoiland, Executive Vice President, U.S., Novo Nordisk; Stelios Papadopoulos, Ph.D., Chairman, Biogen and James Greenwood, President & CEO, BIO — with more to be announced. Visit www.BioNJ.org for continuing updates.

Click here to read this week’s Weekender.